The discovery of immune checkpoint inhibitors (ICIs) that target the programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) axis has revolutionized the treatment of non-small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.